Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Pyrimidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 7/20 | 0.34 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | ALPI | P09923 | 1/20 | 0.31 |
| ▸ | ALPG | P10696 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrimidine SCHEMBL4140222 | 1.00 | FDPS (0.34) | FDPSBTN3A1PDE3ATSHRNAPRT | |
| Pyrimidine SCHEMBL988740 | 1.00 | FDPS (0.34) | FDPSBTN3A1PDE3ATSHRNAPRT | |
| Pyrimidine SCHEMBL4154828 | 1.00 | FDPS (0.34) | FDPSBTN3A1PDE3ATSHRNAPRT | |
| Pyrimidine SCHEMBL28436619 | 0.97 | FDPS (0.33) | FDPSBTN3A1PDE3ATSHRNAPRT | |
| Pyrimidine SCHEMBL27748802 | 0.91 | FDPS (0.31) | FDPSBTN3A1PDE3A | |
| Pyrimidine SCHEMBL27549055 | 0.88 | FDPS (0.32) | FDPSBTN3A1PDE3ATSHRNAPRT | |
| Pyrimidine SCHEMBL28663 | 0.88 | FDPS (0.32) | FDPSBTN3A1PDE3ATSHRNAPRT | |
| Pyrimidine SCHEMBL27549056 | 0.88 | FDPS (0.32) | FDPSBTN3A1PDE3ATSHRNAPRT | |
| Pyrimidine SCHEMBL1880807 | 0.84 | FDPS (0.35) | FDPSBTN3A1PDE3AALPLALPI | |
| Foscarnet SCHEMBL15510548 | 0.83 | FDPS (0.33) | FDPSTSHRNAPRTTDP1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016130562-A2 | METABOLIC ANALYSIS OF THE NUCLEOTIDE DE NOVO AND SALVAGE PATHWAYS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-08-18 | — | — | WO | claimed |
| US-7612047-B2 | Degradation-resistant mononucleoside phosphate compounds | INSPIRE PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | claimed |
| US-20090076256-A1 | DEGRADATION-RESISTANT MONONUCLEOSIDE PHOSPHATE COMPOUNDS | DOUGLASS III JAMES G | 2009-03-19 | — | — | US | claimed |
| US-20030055235-A1 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and \"unnatural\" UDP- and TDP-nucleotide sugars | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-03-20 | — | — | US | claimed |
| WO-2002048331-A2 | ACTIVE-SITE ENGINEERING OF NUCLEOTIDYLTRANSFERASES AND ENZYMATIC METHODS FOR THE SYNTHESIS OF NATURAL AND 'UNNATURAL' UDP- AND NUCLEOTIDE SUGARS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2002-06-20 | — | — | WO | claimed |
| WO-2016130562-A2 | METABOLIC ANALYSIS OF THE NUCLEOTIDE DE NOVO AND SALVAGE PATHWAYS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-08-18 | — | — | WO | disclosed |
| EP-2935664-A1 | STABILIZED NANOPORE AND MICROPORE STRUCTURES AND METHODS FOR MAKING AND USING THE SAME | Ibis Biosciences, Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| CN-102159949-B | Multi-ligand capture agents and related compositions, methods and systems | CALIFORNIA INST OF TECHN | 2015-03-04 | — | — | CN | disclosed |
| WO-2014100693-A1 | STABILIZED NANOPORE AND MICROPORE STRUCTURES AND METHODS FOR MAKING AND USING THE SAME | IBIS BIOSCIENCES, INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| EP-2614156-A2 | CONTROL OF DNA MOVEMENT IN A NANOPORE AT ONE NUCLEOTIDE PRECISION BY A PROCESSIVE ENZYME | The Regents of the University of California (US) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012033524-A2 | CONTROL OF DNA MOVEMENT IN A NANOPORE AT ONE NUCLEOTIDE PRECISION BY A PROCESSIVE ENZYME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-15 | — | — | WO | disclosed |
| CN-102159949-A | Multi-ligand capture agents and related compositions, methods and systems | CALIFORNIA INST OF TECHN | 2011-08-17 | — | — | CN | disclosed |
| US-6111074-A | AMINO ACID SEQUENCE OF POLYPEPTIDE FROM THE URIDINE MONOPHOSPHATE KINASE FAMILY; FOR SCREENING BACTERICIDES AND BACTERIOSTATS; FOR DIAGNOSIS AND PROPHYLAXIS OF INFECTIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-29 | — | — | US | disclosed |
| US-5830653-A | ABILITY TO INHIBIT GENE EXPRESSION | GILEAD SCIENCES, INC. (US) | 1998-11-03 | — | — | US | disclosed |
| US-5645985-A | USED FOR DIAGNOSIS TO DETECT VIRUSES OR DISEASED CONDITIONS | GILEAD SCIENCES, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0724647-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NeXstar Pharmaceuticals, Inc. (US) | 1996-08-07 | — | — | EP | disclosed |
| EP-0637965-A4 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES. | GILEAD SCIENCES INC (US) | 1996-01-24 | — | — | EP | disclosed |
| WO-1995007364-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NEXSTAR PHARMACEUTICALS, INC. (US) | 1995-03-16 | — | — | WO | disclosed |
| EP-0637965-A1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | GILEAD SCIENCES, INC. (US) | 1995-02-15 | — | — | EP | disclosed |
| WO-1993010820-A1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | GILEAD SCIENCES, INC. (US) | 1993-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055235-A1 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and \"unnatural\" UDP- and TDP-nucleotide sugars | PNP, NUDT14, ENTPD5 | FDPS 124/4885BTN3A1 3871/4885PDE3A 2604/4885 |
| US-20090076256-A1 | DEGRADATION-RESISTANT MONONUCLEOSIDE PHOSPHATE COMPOUNDS | PNKP, ENTPD5, ENPP1 | FDPS 184/4885BTN3A1 4600/4885PDE3A 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.